RE:RE:RE:Record breaking Pharma M&A for 2022?First the "no respose thing explained"
There is no way on Gods good Earth that any company, would discusss third party trial parameters, over an email.
Any and all discoloures MUST be dnoe in a public fourm, via SEDAR and other approved media reporting.
Discussing trial details.not made public could be conidered insider information. or minimal "trade secrets"
Now, to answer your first question.
MY Opinion ...Of course they are going to use biomarkers to screen applicants!
ONC has said publicly in previous N.R.s that the whole reaon for Aware-1 was to identify & prove biomarkers "to de-risk" the trial. Dr Matt, as in addition made that statment many times, in quarterly conferences.
So: It is ONCs thoughts to use the biomarkers going forward.
And since A.N. is working in colaboration with ONC it is a safe assumtion that they too would be.
Why cant I.R. just say that?
Its not their trial. and A.N. do what ever they want ( within reason).
Commenting on that would be tottaly out of line.
People think just becasue you/we/I own shares in a company that we are entitled to know every detail of every day.
It is the senior mangenmtns job to run the company under the set parameters of the mission statment, within laws etc.
It is the boards resposibility to oversee high level decsions, that would effect the big picture.
Then every 3 months, they put together a "report" to the shareholders expaining what ahas gone on and why.
As an aexample try emailing Ford Motor company and ak about any of their automotive trials, with electric cars. i.e. types of battery compositions etc? You will not get a reply.
Trade secret.